Information Provided By:
Fly News Breaks for December 3, 2018
AIMT
Dec 3, 2018 | 07:35 EDT
Cantor Fitzgerald analyst Charles Duncan assumed coverage of Aimmune Therapeutics with an Overweight rating and $64 price target. Given the growing unmet clinical need in peanut allergy, AR101 has Breakthrough Therapy and Fast Track designations along with a "high regulatory" probability of success based on data from the Phase 3 Palisade study, Duncan tells investors in a research note.
News For AIMT From the Last 2 Days
There are no results for your query AIMT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.